GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zoetis Inc (NYSE:ZTS) » Definitions » Financial Strength
中文

Zoetis (Zoetis) Financial Strength : 6 (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Zoetis Financial Strength?

Zoetis has the Financial Strength Rank of 6.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

Zoetis's Interest Coverage for the quarter that ended in Dec. 2023 was 12.02. Zoetis's debt to revenue ratio for the quarter that ended in Dec. 2023 was 0.76. As of today, Zoetis's Altman Z-Score is 7.13.


Competitive Comparison of Zoetis's Financial Strength

For the Drug Manufacturers - Specialty & Generic subindustry, Zoetis's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zoetis's Financial Strength Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zoetis's Financial Strength distribution charts can be found below:

* The bar in red indicates where Zoetis's Financial Strength falls into.



Zoetis Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Zoetis's Interest Expense for the months ended in Dec. 2023 was $-59 Mil. Its Operating Income for the months ended in Dec. 2023 was $709 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $6,752 Mil.

Zoetis's Interest Coverage for the quarter that ended in Dec. 2023 is

Interest Coverage=-1*Operating Income (Q: Dec. 2023 )/Interest Expense (Q: Dec. 2023 )
=-1*709/-59
=12.02

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Zoetis's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is

Debt to Revenue Ratio=Total Debt (Q: Dec. 2023 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(3 + 6752) / 8852
=0.76

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Zoetis has a Z-score of 7.13, indicating it is in Safe Zones. This implies the Z-Score is strong.

Good Sign:

Altman Z-score of 7.13 is strong.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zoetis  (NYSE:ZTS) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Zoetis has the Financial Strength Rank of 6.


Zoetis Financial Strength Related Terms

Thank you for viewing the detailed overview of Zoetis's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Zoetis (Zoetis) Business Description

Address
10 Sylvan Way, Parsippany, NJ, USA, 07054
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Executives
Roxanne Lagano officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Kristin C Peck officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Heidi C. Chen officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Robert J Polzer officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Soria Ester Banque officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Rimma Driscoll officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Jamie Brannan officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Vanessa Broadhurst director ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Willie M Reed director C/O ZOETIS, 100 CAMPUS DRIVE, FLORHAM PARK NJ 07932
Nicholas Ashton officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Roman Trawicki officer: Executive Vice President C/O ZOETIS INC., 100 CAMPUS DRIVE, FLORHAM PARK NJ 07932
Glenn David officer: SVP and Acting CFO C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Astorga Jeannette Ferran officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Catherine A. Knupp officer: Executive Vice President C/O ZOETIS INC., 100 CAMPUS DRIVE, FLORHAM PARK NJ 07940
Gregory Norden director 16640 CHESTERFIELD GROVE DRIVE, SUITE 200, CHESTERFIELD MO 63005

Zoetis (Zoetis) Headlines

From GuruFocus

Zoetis Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-23-2024

Q2 2022 Zoetis Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Zoetis Inc Investor Day Transcript

By GuruFocus Research 01-23-2024

Q3 2023 Zoetis Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q3 2022 Zoetis Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q2 2023 Zoetis Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024